- Home
- YOSH vs OVID Comparison
YOSH vs OVID Comparison
Compare YOSH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- OVID
- Stock Information
- Founded
- YOSH 2016
- OVID 2014
- Country
- YOSH United States
- OVID United States
- Employees
- YOSH N/A
- OVID N/A
- Industry
- YOSH Restaurants
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- OVID Health Care
- Exchange
- YOSH Nasdaq
- OVID Nasdaq
- Market Cap
- YOSH 23.7M
- OVID 20.6M
- IPO Year
- YOSH 2022
- OVID 2017
- Fundamental
- Price
- YOSH $8.34
- OVID $0.62
- Analyst Decision
- YOSH
- OVID Strong Buy
- Analyst Count
- YOSH 0
- OVID 4
- Target Price
- YOSH N/A
- OVID $3.13
- AVG Volume (30 Days)
- YOSH 98.4K
- OVID 2.9M
- Earning Date
- YOSH 08-18-2025
- OVID 08-12-2025
- Dividend Yield
- YOSH N/A
- OVID N/A
- EPS Growth
- YOSH N/A
- OVID N/A
- EPS
- YOSH N/A
- OVID N/A
- Revenue
- YOSH $13,539,317.00
- OVID $548,000.00
- Revenue This Year
- YOSH N/A
- OVID N/A
- Revenue Next Year
- YOSH N/A
- OVID $5.32
- P/E Ratio
- YOSH N/A
- OVID N/A
- Revenue Growth
- YOSH 41.82
- OVID 15.61
- 52 Week Low
- YOSH $2.71
- OVID $0.24
- 52 Week High
- YOSH $22.50
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- YOSH 44.35
- OVID 68.33
- Support Level
- YOSH $5.47
- OVID $0.60
- Resistance Level
- YOSH $7.48
- OVID $0.73
- Average True Range (ATR)
- YOSH 1.03
- OVID 0.07
- MACD
- YOSH 0.18
- OVID 0.03
- Stochastic Oscillator
- YOSH 52.09
- OVID 69.12
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.